Table 1.
Relations between miR-618 expression and clinicopathological characteristics of the mCC patients.
| Clinicopathological Characteristics |
High/Intermediate Expression of miR-618 Number (%) |
Low Expression of miR-618 Number (%) |
p-Value |
|---|---|---|---|
| Age | 0.863 | ||
| <65 | 42 (66.7) | 21 (33.3) | |
| ≥65 | 28 (68.3) | 13 (31.7) | |
| Sex | 0.149 | ||
| female | 19 (57.6) | 14 (42.4) | |
| male | 51 (71.8) | 20 (28.2) | |
| Liver Metastasis | 0.102 | ||
| yes | 52 (63.4) | 30 (36.6) | |
| no | 18 (81.8) | 4 (18.2) | |
| Peritoneum Metastasis | 0.753 | ||
| yes | 12 (70.6) | 5 (29.4) | |
| no | 58 (66.7) | 29 (33.8) | |
| Lung Metastasis | 0.422 | ||
| yes | 24 (72.7) | 9 (27.3) | |
| no | 46 (64.8) | 25 (35.2) | |
| RAS | 0.721 | ||
| WT | 34 (65.4) | 18 (34.6) | |
| M+ | 33 (68.8) | 15 (31.3) | |
| Primary Tumor Location | 0.469 | ||
| left colon | 54 (69.2) | 24 (30.8) | |
| right colon | 16 (61.5) | 10 (38.5) | |
| Grade | 0.242 | ||
| low | 60 (69.8) | 26 (30.2) | |
| high | 10 (55.6) | 8 (44.4) | |
| PS (ECOG) | 0.382 | ||
| 0 | 31 (72.1) | 12 (27.9) | |
| 1 | 39 (63.9) | 22 (36.1) | |
| CEA | 0.437 | ||
| ≤2 ULN | 26 (72.2) | 10 (27.8) | |
| >2 ULN | 44 (64.7) | 24 (35.3) |
M+—positive for RAS mutations; WT—wild type; PS (ECOG)—performance status (Eastern Cooperative Oncology Group); ULN—upper limit of normal; CEA—Carcinoembryonic antigen.